Update on hypertrophic cardiomyopathy

Texas Heart Institute Journal

Volumn 37, Issue 3, 2010, Pages 322-323

  Marian, Ali J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT;

ARTICLE; CAUSE OF DEATH; DRUG EFFICACY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PATHOGENESIS; SUDDEN DEATH; CARDIOMYOPATHY, HYPERTROPHIC; COMPLICATION; CONVALESCENCE; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION; GENETICS; PATHOPHYSIOLOGY; PHENOTYPE; RISK FACTOR; TREATMENT OUTCOME;

CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR AGENTS; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; RECOVERY OF FUNCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 77955400085     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287(10):1308-20.
2. Marian AJ. Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol 2008;23(3):199-205.
3. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119 (8):1085-1092.
4. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355(9197):58-60.
5. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomy-opathy. Circulation 2001;104(3):317-324.
6. Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005;97(3):285-292.
7. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109(10):1284-91.
8. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006;47(4):827-834.
9. Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J, et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiolsensitive mechanisms. Circulation 2009;119(10):1398-407.